Mouse CD4+CD25+ T regulatory cells are protected from autologous complement mediated injury by Crry and CD59

Biochemical and Biophysical Research Communications

Volumn 382, Issue 1, 2009, Pages 223-226

  Li, Qing ^a,b   Nacion, Kristine ^b   Bu, Hong ^a   Lin, Feng ^b  

^a SICHUAN UNIVERSITY   (China)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Complement; Complement regulators; foxp3; Mouse; Treg cells

Indexed keywords

CD59 ANTIGEN; CD97 ANTIGEN; CELL PROTEIN; CRRY PROTEIN; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNITY; CD4+ CD25+ T LYMPHOCYTE; CELL PROTECTION; CELL SURFACE; COMPLEMENT INHIBITION; FEMALE; GENE EXPRESSION REGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD4; ANTIGENS, CD55; ANTIGENS, CD59; COMPLEMENT C3B; COMPLEMENT SYSTEM PROTEINS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MICE; MICE, MUTANT STRAINS; RECEPTORS, COMPLEMENT; T-LYMPHOCYTES, REGULATORY;

MUS;

EID: 63149099729     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.03.025     Document Type: Article

References (30)

1. K. Rother, G.G. Till (Eds.), The Complement System, Springer, 1988. ISBN 3-540-18205-5.
2. Ehlenberger A.G., and Nussenzweig V. The role of membrane receptors for C3b and C3d in phagocytosis. J. Exp. Med. 145 (1977) 357-371
3. Podack E.R., Biesecker G., and Muller-Eberhard H.J. Membrane attack complex of complement: generation of high-affinity phospholipid binding sites by fusion of five hydrophilic plasma proteins. Proc. Natl. Acad. Sci. USA 76 (1979) 897-901
4. Medof M.E., Kinoshita T., and Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J. Exp. Med. 160 (1984) 1558-1578
5. Seya T., Turner J.R., and Atkinson J.P. Purification and characterization of a membrane protein (gp45-70) that is a cofactor for cleavage of C3b and C4b. J. Exp. Med. 163 (1986) 837-855
6. Klickstein L.B., Bartow T.J., Miletic V., Rabson L.D., Smith J.A., and Fearon D.T. Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis. J. Exp. Med. 168 (1988) 1699-1717
7. Zalman L.S., Wood L.M., and Muller-Eberhard H.J. Inhibition of antibody-dependent lymphocyte cytotoxicity by homologous restriction factor incorporated into target cell membranes. J. Exp. Med. 166 (1987) 947-955
8. Miwa T., and Song W.C. Membrane complement regulatory proteins: insight from animal studies and relevance to human diseases. Int. Immunopharmacol. 1 (2001) 445-459
9. Kim Y.U., Kinoshita T., Molina H., Hourcade D., Seya T., Wagner L.M., and Holers V.M. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein. J. Exp. Med. 181 (1995) 151-159
10. Tsujimura A., Shida K., Kitamura M., Nomura M., Takeda J., Tanaka H., Matsumoto M., Matsumiya K., Okuyama A., Nishimune Y., Okabe M., and Seya T. Molecular cloning of a murine homologue of membrane cofactor protein (CD46): preferential expression in testicular germ cells. Biochem. J. 330 Pt. 1 (1998) 163-168
11. Lin F., Fukuoka Y., Spicer A., Ohta R., Okada N., Harris C.L., Emancipator S.N., and Medof M.E. Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes. Exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies. Immunology 104 (2001) 215-225
12. Xu C., Mao D., Holers V.M., Palanca B., Cheng A.M., and Molina H. A critical role for murine complement regulator Crry in fetomaternal tolerance. Science 287 (2000) 498-501
13. + regulatory T cells in autoimmune diseases. Nat. Clin. Pract. Rheumatol. 3 (2007) 619-626
14. + regulatory T cells in transplantation: progress, challenges and prospects. Am. J. Transplant. 7 (2007) 1457-1463
15. Holt D.S., Botto M., Bygrave A.E., Hanna S.M., Walport M.J., and Morgan B.P. Targeted deletion of the CD59 gene causes spontaneous intravascular hemolysis and hemoglobinuria. Blood 98 (2001) 442-449
16. Spiller O.B., Harris C.L., and Morgan B.P. Efficient generation of monoclonal antibodies against surface-expressed proteins by hyperexpression in rodent cells. J. Immunol. Methods 224 (1999) 51-60
17. Quigg R.J., Holers V.M., Morgan B.P., and Sneed III A.E. Crry and CD59 regulate complement in rat glomerular epithelial cells and are inhibited by the nephritogenic antibody of passive Heymann nephritis. J. Immunol. 154 (1995) 3437-3443
18. Quigg R.J., Nicholson-Weller A., Cybulsky A.V., Badalamenti J., and Salant D.J. Decay accelerating factor regulates complement activation on glomerular epithelial cells. J. Immunol. 142 (1989) 877-882
19. Law S.K., Lichtenberg N.A., and Levine R.P. Covalent binding and hemolytic activity of complement proteins. Proc. Natl. Acad. Sci. USA 77 (1980) 7194-7198
20. Medof M.E., Iida K., and Nussenzweig V. Role of the complement receptor CR1 in the processing of substrate-bound C3. Ann. NY Acad. Sci. 421 (1983) 299-306
21. Meri S., Morgan B.P., Davies A., Daniels R.H., Olavesen M.G., Waldmann H., and Lachmann P.J. Human protectin (CD59), an 18, 000-20, 000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 71 (1990) 1-9
22. Zalman L.S., Wood L.M., Frank M.M., and Muller-Eberhard H.J. Deficiency of the homologous restriction factor in paroxysmal nocturnal hemoglobinuria. J. Exp. Med. 165 (1987) 572-577
23. Richards A., Kathryn Liszewski M., Kavanagh D., Fang C.J., Moulton E., Fremeaux-Bacchi V., Remuzzi G., Noris M., Goodship T.H., and Atkinson J.P. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol. Immunol. 44 (2007) 111-122
24. Lin F., Emancipator S.N., Salant D.J., and Medof M.E. Decay-accelerating factor confers protection against complement-mediated podocyte injury in acute nephrotoxic nephritis. Lab. Invest. 82 (2002) 563-569
25. Lin F., Kaminski H.J., Conti-Fine B.M., Wang W., Richmonds C., and Medof M.E. Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. J. Clin. Invest. 110 (2002) 1269-1274
26. Zheng Y., Josefowicz S.Z., Kas A., Chu T.T., Gavin M.A., and Rudensky A.Y. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 445 (2007) 936-940
27. Teague T.K., Hildeman D., Kedl R.M., Mitchell T., Rees W., Schaefer B.C., Bender J., Kappler J., and Marrack P. Activation changes the spectrum but not the diversity of genes expressed by T cells. Proc. Natl. Acad. Sci. USA 96 (1999) 12691-12696
28. Heeger P.S., Lalli P.N., Lin F., Valujskikh A., Liu J., Muqim N., Xu Y., and Medof M.E. Decay-accelerating factor modulates induction of T cell immunity. J. Exp. Med. 201 (2005) 1523-1530
29. Nicholson-Weller A., Russian D.A., and Austen K.F. Natural killer cells are deficient in the surface expression of the complement regulatory protein, decay accelerating factor (DAF). J. Immunol. 137 (1986) 1275-1279
30. Finberg R.W., White W., and Nicholson-Weller A. Decay-accelerating factor expression on either effector or target cells inhibits cytotoxicity by human natural killer cells. J. Immunol. 149 (1992) 2055-2060